Search for Clinical Trial Results

Sponsored By

Nephrogenic Systemic Fibrosis - 15 Studies Found

Status Study
Completed Study Name: Validation of a Questionnaire to Identify Signs and Symptoms of Nephrogenic Systemic Fibrosis
Condition: Nephrogenic Systemic Fibrosis
Date: 2009-03-17
Completed Study Name: Treatment of Patients With Nephrogenic Systemic Fibrosis With Glivec
Condition: Nephrogenic Systemic Fibrosis
Date: 2009-09-21
Interventions: Drug: Imatinib mesylate (Glivec) 400 mg, one tablet daily for 12 or 24 weeks
Completed Study Name: Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis
Condition: Nephrogenic Systemic Fibrosis
Date: 2008-05-08
Interventions: Drug: Imatinib mesylate 400 mg p.o. daily for 4 months. Dosage was reduced to 200 mg if participants dev
Terminated Study Name: Plasmapheresis for Nephrogenic Fibrosing Dermopathy (NFD)/Nephrogenic Systemic Fibrosis (NSF)
Condition:
  • Nephrogenic Fibrosing Dermopathy
  • Nephroge
    Date: 2010-02-05
    Interventions: Procedure: Plasmapheresis A course of 5 daily treatments of plasma exchange (plasmapheresis) for one to
Completed Study Name: Nephrogenic Systemic Fibrosis (NSF): Analysis of Tissue Gadolinium Levels
Condition:
  • Nephrogenic Systemic Fibrosis
  • Nephrogenic
    Date: 2009-11-13
Suspended Study Name: Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following OptiMARK Injection
Condition:
  • Nephrogenic Systemic Fibrosis
  • Renal Insufficiency

Date: 2008-12-18
Suspended Study Name: Nephrogenic Systemic Fibrosis With Gadollinum
Condition:
  • Nephrogenic Systemic Fibrosis
  • Renal Failure

Date: 2009-10-26
Interventions: Drug: gadollinum use of on injection gadollinum Iv for imaging
Completed Study Name: Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MR
Condition: Nephrogenic Systemic Fibrosis
Date: 2010-06-01
Interventions: Drug: Ablavar One dose of Ablavar will be administered for use during a contrast MRI examination
Completed Study Name: Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist
Condition:
  • Fibrosis
  • Kidney Failure
  • Renal Insufficiency

Date: 2008-08-20
Interventions: Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882) Patients will be followed for 2 years after the
Completed Study Name: Evaluation of the Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Without Exposure to Gadolinium Based Contrast Agents (GBCA)
Condition: Renal Insufficiency
Date: 2008-10-15
Next >>>